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Abstract 
Small cell lung cancer (SCLC) is a smoking-induced malignancy with multiple toxin-
associated mutations, which accounts for 15% of all lung cancers. It remains a clinical 
challenge with a rapid doubling time, early dissemination and poor prognosis. 
Despite multiple clinical trials in SCLC, platinum-based chemotherapy remains the 
mainstay of treatment in the advanced first line setting. Good initial responses are 
nevertheless inevitably followed by disease relapse and survival remains poor. There 
are currently no molecularly targeted agents licensed for use in SCLC. Advances in 
sequencing the cancer genome and other high-throughput profiling technologies 
have identified aberrant pathways and mechanisms implicated in SCLC development 
and progression. Novel anti-tumour therapeutics that impact these putative targets 
are now being developed and investigated in SCLC. In this review, we discuss novel 
anti-tumour agents assessed in SCLC with reference to the complex molecular 
mechanisms implicated in SCLC development and progression. We focus on novel 
DNA damage response inhibitors, immune checkpoint modulators and antibody-drug 
conjugates (ADCs) that have shown promise in SCLC, and which may potentially 
transform treatment strategies in this disease. Finally, we envision the future 
management of SCLC and propose a biomarker-driven translational treatment 
paradigm for SCLC that incorporates next generation sequencing studies with patient 
tumours, circulating plasma DNA and functional imaging. Such modern strategies 
have the potential to transform the management and improve patient outcomes in 
this disease.   
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Introduction 
Lung cancer is the leading cause of cancer-related deaths globally [1, 2]. Small cell 
lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with a 
propensity to present with metastatic disease (extensive stage disease; ED) at an 
early stage [3, 4]. Our understanding of the complex molecular mechanisms and 
pathways underpinning the development and progression of SCLC has improved with 
recent advancements in cancer genome sequencing and other high throughput 
profiling technologies [5-12]. However, despite these advances, there have been no 
significant improvements in the development of anti-tumour strategies for this 
disease. A plethora of molecular targeted agents have been investigated in SCLC and 
most have failed to demonstrate clinical benefit [13-45]. This is likely due to a 
combination of the molecular targets selected, their functional relevance in the 
pathogenesis of this aggressive disease and the lack of predictive biomarkers for 
their clinical efficacy in SCLC, making appropriate patient selection challenging. 
 
Given the richness of the leads that have been produced with high throughput 
profiling technologies in other solid malignancies as well as liquid tumours, there is 
now a fresh impetus to exploit these technologies in SCLC. Here we detail novel 
therapies that have been investigated in patients with SCLC in the context of our 
expanding knowledge of the molecular biology underpinning the disease. We also 
propose treatment strategies that we believe will provide SCLC patients with the 
greatest chance of clinical benefit.   
 
Development of novel agents in SCLC: the challenges 
A number of molecularly targeted therapies have been evaluated in SCLC either as 
monotherapy or in combination with other anti-tumour agents. These include 
clinical trials in the first-line setting, as maintenance therapy and in relapsed SCLC 
(Table 1-2) [13-45]. The majority of these trials have not found a benefit probably 
due to both disease and trial-related issues. For example, undertaking clinical trials 
in SCLC is particularly challenging as patients commonly present with disease-related 
symptoms requiring urgent systemic chemotherapy. Therefore, the time required in 
performing comprehensive genomic analysis and screening for clinical trial entry is 
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often to the detriment of the patients’ performance status and symptoms. This is 
highlighted by the relatively small number of patients enrolled into clinical trials of 
targeted therapies in SCLC (Table 1-2) [13-45]. As SCLC is a chemosensitive disease, 
with platinum-based chemotherapy inducing high response rates of 75-95% and 
improving patient survival, it is also difficult to demonstrate an improved response 
rate from targeted therapies used as adjuncts to chemotherapy in the first-line 
treatment of SCLC without very large numbers of patients [46]. However, despite 
these initial high response rates observed with chemotherapy, patients with SCLC 
inevitably relapse. An attractive approach is thus to explore the use of molecularly 
targeted therapies in the maintenance setting to prolong treatment responses. This 
approach is especially relevant in SCLC, as patients on relapse often undergo rapid 
clinical deterioration, making treatment within or outwith a clinical trial challenging.  
 
Drug development in SCLC: pitfalls and promises 
Targeting angiogenesis, cell signalling and apoptosis. 
Overall, clinical trials evaluating molecularly targeted therapies that inhibit 
angiogenesis, cell signalling and apoptosis in SCLC have been disappointing (Tables 
1-2; Figure 1).  Angiogenesis plays an important role in tumour growth, invasion and 
metastasis [47]. Vascular endothelial growth factors (VEGFs) stimulate cancer cell 
migration, invasion, vascular permeability and vessel formation, and have been 
shown to increase tumour growth and angiogenesis in pre-clinical models [48]. 
Increased levels of VEGF-A and high vascular counts are associated with a poor 
prognosis in SCLC [48-50]. Moreover, aberrations within the VEGF pathway have 
been identified in SCLC, the majority of which occur downstream of the VEGF:VEGFR 
interaction (Table 3; Figure 1) [5-7]. These pre-clinical studies suggest that targeting 
angiogenesis is an attractive strategy for the treatment of SCLC. Disappointingly, 
nearly all trials of targeted agents inhibiting angiogenesis have demonstrated little or 
no clinical benefit in SCLC (Tables 1-2; Figure 1) [13, 19-22, 25-28, 30, 31, 33-35, 37, 
41, 45].  
 
An area of potential promise is sunitinib, a small molecule inhibitor of multiple 
tyrosine kinase receptors, that has shown anti-tumour activity in clinical trials (Figure 
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1; Table 1-2) [51]. Ready and colleagues investigated maintenance sunitinib after 
platinum and etoposide chemotherapy in untreated ED SCLC. Progression free 
survival (PFS) and overall survival (OS) of patients receiving maintenance sunitinib 
were 3.7 and 9.0 months compared to 2.1 and 6.9 months, respectively, in those 
patients receiving placebo. The improvement in PFS was significant (P=0.02). The 
most common grade 3-4 toxicities were fatigue (19%) and neutropenia (14%) [22]. 
Spigel and colleagues demonstrated the anti-tumour potential (PFS 7.6 months; OS 
at 1 year was 54%) of sunitinib as maintenance therapy in patients with ED SCLC with 
no evidence of progressive disease after first line chemotherapy with irinotecan and 
carboplatin [26].  
 
Sunitinib as monotherapy in patients with relapsed SCLC has not been well studied. 
Sunitinib was poorly tolerated (63% grade 3-4 thrombocytopenia; 25% grade 3-4 
neutropenia) in a phase II study, with little activity in patients who 
relapsed/progressed after chemotherapy [35]. Recently, Abdelraouf and colleagues 
reported anecdotal responses, comprising a RECIST partial response lasting 10 
months and a second patient with stable disease that lasted 20 months, out of a 
small cohort of nine patients (7 chemosensitive and 2 chemotherapy-naïve) treated 
with sunitinib monotherapy [52]. Grade 3-4 thrombocytopenia and neutropenia 
were observed in 33% of patients treated with sunitinib. The activity of sunitinib in 
SCLC may thus warrant further investigation. Future studies should incorporate the 
exploration of predictive biomarkers of response to identify patients with SCLC who 
are most likely to benefit from treatment with sunitinib. 
 
Aberrations in EGFR, c-KIT, PI3K/AKT/mTOR, IGFR1 and hedgehog signalling 
pathways have been identified in SCLC (Table 3; Figure 1) [5-12, 53].  Preclinical 
studies have reported overexpression of c-kit and IGFR1, and activation of Hedgehog 
signalling in SCLC [38, 53-55]. Ross and colleagues performed targeted exome 
sequencing of 236 cancer-related genes in ED SCLC and identified molecular 
aberrations in a number of cell-signaling networks including rapamycin-insensitive 
companion of mTOR (RICTOR; 10%), stem cell factor receptor tyrosine kinase (c-KIT; 
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7%), PI3K catalytic subunit alpha (PIK3CA; 6%), epidermal growth factor receptor 
(EGFR; 5%), phosphatase and tensin homolog (PTEN; 5%) and KRAS (5%) (Table 3) 
[6]. Similarly, Umemura and colleagues identified high prevalence of genetic 
mutations including PIK3CA (6% of cases), PTEN (4%), RICTOR (9%) and mTOR (4%) 
(Table 3) [11]. Therapies targeting EGFR, c-KIT, PI3K/AKT/mTOR, IGFR1 and 
hedgehog pathway inhibitors have disappointingly demonstrated minimal efficacy in 
first-line, maintenance and relapsed SCLC (Tables 1-2; Figure 1) [14, 15, 18, 24, 29, 
38, 40, 43].  
 
Therapeutic strategies that induce apoptosis in SCLC have also been explored in 
preclinical and clinical studies. The anti-apoptotic protein BCL-2 is expressed in SCLC 
and correlates with poor prognosis [56]. In addition, inhibition of the proteasome by 
bortezomib is associated with a reduction in BCL-2 levels and induction of apoptosis 
in SCLC cell lines [57]. Similarly, HDAC inhibition reduces the growth of SCLC cell lines 
and xenografts [58]. Targeted therapies that inhibit BCL-2 family proteins, HDACs 
and the proteasome have demonstrated no benefit in patients with SCLC (Tables 1-
2; Figure 1) [16, 23, 32, 36, 39, 42].  
 
Overall, despite both widespread comprehensive genome analysis and pre-clinical 
studies implicating angiogenesis, cell signalling and apoptosis in the pathogenesis of 
SCLC, therapies that target these pathways have demonstrated little or no efficacy in 
clinical trials (Tables 1-3; Figure 1) [5-7, 11, 13-16, 18-43, 45, 47-50, 53-55, 57, 58]. 
These results are likely multifactorial. The aberrations identified in recent genome 
analyses may be present, but are probably not critical for the pathogenesis of SCLC. 
Therefore, translational studies to understand the consequence of these aberrations 
are urgently required. In addition, if such abnormalities are critical for the 
progression and development of SCLC, then only those patients harboring such 
aberrations are likely to benefit from treatment and therefore, clinical trials of 
targeted therapies in small-unselected populations are unlikely to show clinical 
benefit. Finally, most of those agents discussed have been developed for other 
tumour types rather than SCLC. In the future, it will be important to discover new 
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targets and develop targeted therapies based on the underlying biological drivers of 
SCLC.  
 
Targeting DNA repair pathways 
Transcriptional regulation and DNA repair pathways have been implicated in SCLC 
development. Sequencing of SCLC surgical samples has identified a high prevalence 
of inactivating mutations in TP53 and RB1, amplification of MYC family members and 
mutations of histone modifiers (CREBBP and EP300) (Table 3) [6, 9-11]. Similarly, 
SCLC has a very high level of poly(ADP-ribose) polymerase 1 (PARP1) expression 
compared to other solid tumours implicating a potential role in SCLC [59]. PARP1 is a 
highly abundant nuclear protein that is activated in response to DNA damage [60]. 
The PARP1 enzyme has a critical function in DNA damage recognition and 
subsequent repair through base excision repair and has a role in homologous 
recombinant repair [17, 60]. Loss of PARP1 activity in pre-clinical models leads to the 
accumulation of DNA strand breaks along with sensitization to radiotherapy and 
chemotherapy [17, 60-62]. Sensitization seems to be a result of increased DNA 
damage and delayed DNA damage repair [17]. Platinum-based chemotherapy 
induces high response rates in SCLC, and the use of PARP inhibitors to prevent the 
ability of cancer cells to repair DNA damage induced by cytotoxic agents is thus an 
attractive therapeutic strategy for the treatment of SCLC (Figure 1).  
 
The safety of the PARP inhibitor veliparib in combination with cisplatin and 
etoposide in first-line treatment of ED SCLC has been evaluated in the clinic (Table 1) 
[63]. The addition of veliparib to cisplatin and etoposide did not improve the 
response rate beyond that expected for chemotherapy alone [63]. PARP inhibitors 
may demonstrate clinical benefit as maintenance treatment in patients with 
platinum sensitive disease through the prolonged inhibition of DNA repair pathways. 
Olaparib is currently being evaluated in a randomised placebo-controlled phase II 
study as maintenance therapy in SCLC after RECIST response to first-line 
chemotherapy (ISRCTN 73164486) (Table 1). Wainberg and colleagues evaluated the 
PARP inhibitor BMN-673 in ED SCLC patients that progressed after platinum-based 
chemotherapy (Table 2) [44]. Single agent treatment was well tolerated (4.3% grade 
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3-4 toxicities) and two of 11 evaluable patients (18%) with SCLC demonstrated 
RECIST partial responses [44]. 
 
Multiple putative predictive biomarkers of platinum sensitivity and clinical outcomes 
in SCLC have been investigated [3, 64]. Karachaliou and colleagues identified a gene 
expression signature from 184 patients with SCLC treated with cisplatin and 
etoposide [3]. This favorable expression signature (low levels of excision repair cross 
complementation group 1, pyruvate kinase isoform M2, DNA topoisomerase I and 
DNA topoisomerase II mRNA) correlated with improved PFS and OS in patients with 
both limited disease (LD) (P<0.001 and P=0.007, respectively) and ED (P=0.007 and 
P=0.011, respectively) SCLC [3]. BMN-673 demonstrates anti-tumour activity in SCLC 
cell lines and xenografts [65]. The elevated expression of 17 DNA repair proteins as 
well as higher levels of expression of a novel “DNA repair protein score” predicted 
anti-tumour responses to BMN-673. In addition, PI3K activation was associated with 
resistance to BMN-673 [65]. These findings need to be validated in patients with 
SCLC as they may identify biomarkers that may predict for response and resistance 
to BMN-673. Germline BRCA1 and BRCA2 mutations in SCLC are low. However, the 
numerous somatic aberrations seen within DNA repair proteins mean SCLCs possess 
a BRCAness phenotype with potential associated sensitivity to platinum therapy and 
novel targeted agents such as PARP and ataxia telangiectasia and Rad3-related 
protein (ATR) inhibitors [66]. Therapies that target DNA repair defects in SCLC in an 
appropriately selected population have the potential to transform the treatment of 
this aggressive disease. The proposed BRCAness phenotype of SCLC, molecular 
alterations in transcriptional regulation, and observed early anti-tumour responses 
to BMN-673 in relapsed SCLC warrant further investigation with the exploration of 
biomarker-defined patient subgroups. 
 
Targeting the immune system  
Immune modulation provides an attractive method to harness a patients immune 
system to achieve tumour control, stabilisation and potential eradication of disease 
[67]. T-cells play a central role in cell-mediated immunity (Figure 2). Briefly, T-cell 
activation occurs when exposure to tumour antigen is followed by antigen 
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independent co-regulatory signals. This leads to the activation and mobilisation of T-
cells (Figure 2) [68, 69]. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is 
expressed on activated T-cells and down regulates the T-cell response [70]. Activated 
T-cells mobilise to the tumour microenvironment, where if they recognise antigens 
expressed on the tumour cell, they proliferate, release cytolytic enzymes and secrete 
cytokines that attract other members of the immune system and eliminate tumour 
cells (Figure 2). In comparison, programmed cell death protein-1 (PD-1) is expressed 
on activated T-cells, which binds to its ligand PD-L1, causing T-cell inhibition. Tumour 
cells hijack this pathway by expressing PD-L1 on their cell surface and directly 
suppressing anti-tumour cytotoxic T-cell activity and thus evading the immune 
system (Figure 2). Immune therapies that overcome inhibition of the immune 
system by targeting CTLA-4, PD-1 and PD-L1 have shown great promise as novel anti-
cancer therapies in multiple malignancies [67]. 
 
Ipilimumab (CTLA-4 monoclonal antibody) has been evaluated in combination with 
carboplatin and paclitaxel chemotherapy in first line treatment of patients with ED 
SCLC (Table 1) [71]. In a pivotal 3-arm phase II trial, patients received either 6 cycles 
of carboplatin and paclitaxel with or without ipilimumab or with ipilimumab in a 
phased schedule [71]. Phased ipilimumab was associated with improved immune 
related PFS when compared to the control arm (P=0.03) [71]. There was a trend 
towards improved OS in the phased ipilimumab arm (P=0.13). The incidence of grade 
3-4 toxicities was greater with ipilimumab treatment (phased 50%, concurrent 43%) 
than without (30%). This study did not identify any potential biomarkers that may 
predict for response to ipilimumab treatment in patients with SCLC. Further clinical 
trials are now ongoing to evaluate ipilimumab with and without chemotherapy in LD 
and ED SCLC (NCT01331525, NCT02046733 and NCT01450761). 
 
Nivolumab and pembrolizumab are novel high-affinity, humanized monoclonal 
antibodies that block PD-1. Nivolumab is currently being investigated as 
monotherapy or in combination with ipilimumab in advanced tumours, including 
SCLC (NCT01928394). Monoclonal antibodies that block PD-L1 (BMS 936559, 
MEDI4736 and MPDL3280A) are also being evaluated in early phase clinical trials in 
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advanced cancers. Pembrolizumab demonstrated promising antitumor activity in the 
KEYNOTE-028 trial involving patients with heavily pretreated, PD-L1–positive, 
extensive-stage SCLC (Table 2) [72]. Patients received 10 mg/kg of intravenous 
pembrolizumab once every 2 weeks. Response was assessed every 8 weeks for the 
first 6 months, then every 12 weeks thereafter. Overall, the safety and toxicity 
profile was consistent with previous studies with pembrolizumab in other tumor 
types. Treatment-related adverse events affecting two or more patients occurred in 
14 patients; two patients had grade 3-5 adverse events, including one case of colitis 
that resulted in the patient’s death. One case of grade 2 autoimmune thyroiditis 
resulted in treatment interruption [72]. The overall response rate to pembrolizumab 
in antitumor activity was 35% (95% CI [15%, 59%]), and the responses appeared 
durable, with six of seven ongoing at data cutoff. The median time to response was 
8.6 weeks (range: 7.7-16.1 weeks), while the median duration of response was 29.1 
weeks (range: 0.1-29.1 weeks). Five of seven patients who had a disease response 
had reduction in tumor size from baseline of 50% or greater [72]. Interestingly, six of 
seven responses occurred after 8 weeks of initiating treatment, and one patient who 
had stable disease at 8 weeks then had a partial response at 16 weeks. 
 
The distinct roles of CTLA-4 and PD-1/PD-L1 in regulating T-cell activation suggests 
there is merit in exploring dual blockade (Figure 2). Combined blockade with CTLA-4, 
PD-1 and PD-L1 antibodies inhibit growth in pre-clinical melanoma models [73]. 
CTLA-4 inhibition has been shown to upregulate PD-1 on tumour infiltrating cells 
while PD-1 inhibition has been shown to upregulate CTLA-4 on tumour infiltrating 
cells [73]. This potentially provides a mechanism of resistance to immune 
monotherapy and therapeutic strategies that block CTLA-4 and PD-1 may 
demonstrate synergistic benefit in patients. The phase I/II CheckMate 032 study of 
nivolumab with or without ipilimumab for patients with recurrent SCLC 
demonstrated that both nivolumab monotherapy and the nivolumab/ipilimumab 
combination therapy showed activity and durable responses in patients with SCLC 
(Table 2) [74]. The study comprised four arms, and included 128 patients with 
progressive disease after one or more lines of therapy, including a first-line 
platinum-based regimen. One arm received 3 mg/kg of intravenous nivolumab every 
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2 weeks (40 patients), and two arms received 1 mg/kg of intravenous nivolumab in 
combination with either 1 mg/kg or 3 mg/kg of intravenous ipilimumab every 3 
weeks for four cycles (3 patients and 47 patients, respectively). Data have not been 
reported from the fourth arm, which included 3 mg/kg of intravenous nivolumab 
plus 1 mg/kg of intravenous ipilimumab every 3 weeks for four cycles [74]. 
 
Fifteen percent of patients in the arm treated with nivolumab monotherapy had 
grade 3-4 adverse events; 34% had grade 3-4 adverse events in the arm treated with 
nivolumab plus the higher dose (3 mg/kg) of ipilimumab. One patient died from 
treatment-related causes (myasthenia gravis) in the combination arm receiving the 
higher dose of ipilimumab. The ORR was 18% with nivolumab monotherapy and 17% 
with nivolumab/ipilimumab. The disease control rate was 38% with monotherapy 
and 54% with combination therapy. The median OS was 4.4 months with 
monotherapy (95% CI [2.9, 9.4]) and 8.2 months with combination therapy (95% CI 
[3.7, not reached]). Overall, the response rate and frequency of tumor reduction 
suggested increased effects with the combination, activity was observed in both 
platinum-sensitive and platinum-resistant/refractory disease. Interestingly, 
responses occurred regardless of PD-L1 expression.  
 
Only a subset of patients treated with immune therapies experience durable and 
long-term disease control [67, 72, 74]. It will therefore be important to identify 
predictive biomarkers of response to identify those patients that will benefit most 
from CTLA-4 and/or PD-1/PD-L1 targeting. For example, PD-L1 expression is 
currently the closest we have to a predictive biomarker at this point of time for PD-
1/PD-L1 inhibitors, but is clearly imperfect [67]. Variations in laboratory assays, 
tumour type and previous treatments may contribute to observed heterogeneity in 
PD-L1 expression [67]. Making treatment decisions on such a biomarker requires 
careful consideration since many who are biomarker negative may still benefit. It is 
likely that the selection of biomarkers for PD-L1/PD-1 inhibitors will involve 
additional factors, such as non-synonymous mutational load. Candidate neo-
antigens have been identified that bind with high affinity to MHC class I receptors, 
which may predict for anti-tumour responses to both CTLA-4 and PD-1 treatments 
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[75]. Patients with NSCLC harbouring tumors with high candidate neoantigen burden 
had improved outcomes compared to controls when treated with pembrolizumab 
(median PFS 14.5 months versus 3.5 months p=0.002) [76]. The application of 
neoantigen burden as a predictive biomarker of response to different 
immunotherapies is promising and should be explored in future clinical trials.  
 
Antibody-drug conjugates (ADCs)  
A number of antibodies that target tumor surface antigens have provided effective 
anti-cancer therapies [77]. However, many unmodified antibodies lack therapeutic 
activity and are instead being exploited to deliver potent cytotoxic drugs in the form 
of ADCs. Neural cell adhesion molecule (also called CD56) is expressed on the cell 
surface of SCLC (approximately 74%) [78, 79]. Lorvotuzumab mertansine (LM) is an 
antibody drug conjugate (ADC) containing a CD56 binding antibody (N901) bound to 
the microtubulin disruptive agent DM-1. LM has demonstrated activity in pre-clinical 
models of SCLC both as monotherapy and in combination with chemotherapy [79, 
80]. In two Phase I studies involving CD56-positive solid tumors, the CBR (partial 
responses plus stable disease for ≥ 75 days) was 25% (17/68 patients) in patients 
with small cell lung cancer (SCLC) from among 113 patients treated with LM [81]. 
Despite initial promise, a phase II study of LM in combination with carboplatin and 
etoposide was stopped early by the independent data monitoring committee due to 
concerns with efficacy of the combination and LM has not been developed further in 
SCLC. 
 
Rovalpituzumab tesirine, an ADC comprised of a humanized anti-delta-like 3 (DLL3) 
monoclonal antibody conjugated to the DNA-damaging pyrrolobenzodiazepine (PDB) 
dimer toxin, has shown promising activity in SCLC [82]. DLL3 expression by 
immunohistochemistry is elevated in SCLC (72 to 85%), compared to 
adenocarcinoma (3.7%), squamous cell carcinoma (0%) and normal lung tissue (0%) 
[82]. DDL3 is overexpressed in primary SCLC and patient derived xenografts 
compared to normal tissue [82]. Treatment with rovalpituzumab tesirine induced 
durable responses in SCLC patient derived xenograft tumour models and eliminated 
tumour initiating cells which are not effected by standard therapies and are thought 
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to be responsible for the rapid disease relapse seen clinically in SCLC [82].  The 
efficacy of rovalpituzumab tesirine is a consequence of targeted delivery of PDB 
dimer toxin either as naked anti-DLL3 antibody or free PDB dimer toxin had anti-
tumour activity [82].  These encouraging pre-clinical data are supported by a recent 
first-in-human phase I trial of rovalpituzumab tesirine in patients with recurrent 
SCLC. In all evaluable patients (n=32), the overall response rate was 22% (n=7 partial 
response), together with disease stabilization in 53% (n=17) of patients [83]. Sixteen 
patients had confirmed DLL3 positivity (H-Score ≥ 120) and of these, 7 patients (44%) 
had partial response and 8 patients (50%) achieved stable disease [83]. Grade 3-4 
toxicities were capillary leak syndrome (14%) and thrombocytopenia (6%) [83].  
Rovalpituzumab tesirine in DLL3 positive patients is a promising treatment strategy, 
and the first in this class of drugs to show activity in SCLC. If these results can be 
reproduced in the planned follow-on trials, then rovalpituzumab tesirine has the 
potential to transform the treatment of relapsed SCLC. 
 
Developing targeted therapies in SCLC: how can we improve?  
Over the past 10 years, molecularly targeted agents have altered the management 
of different malignancies, with significant patient benefit observed in biomarker 
selected groups of patients. Despite the successes observed in multiple solid 
tumours, there are still no targeted therapies approved for use in SCLC and there are 
a number of reasons for these short fallings. Firstly, most agents explored in SCLC 
have showed promise in other tumour types and have not been discovered or 
developed specifically against the underlying biology of SCLC. Secondly, despite our 
increase in the understanding of the molecular characteristics of SCLC, the 
development of SCLC targeted treatments has continued in small underpowered 
phase II studies involving unselected patients. We have learnt little from such 
studies, and they have failed to demonstrate clinical benefit in selected groups of 
patients with SCLC, resulting in a paucity of phase III studies involving targeted 
agents in this disease. 
 
Translational research that identifies molecular aberrations from extensive whole 
genome analysis that are critical for SCLC development is urgently required. 
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Correlation of these findings with clinical endpoints is of paramount importance and 
these studies have the potential to identify predictive biomarkers that determine 
patient cohorts most likely to respond to molecularly targeted therapies and 
immunotherapies. One constraint to such translational studies is the paucity of 
tissue for molecular studies since SCLC is rarely resected and serial biopsies are a 
major challenge. Therefore, alternative sources of tissue including circulating tumour 
cells (CTCs) and circulating plasma DNA (cpDNA) needs to be identified for such 
translational studies. Moreover, translational studies that can identify molecular 
mechanisms of resistance in patients progressing on treatment with targeted 
therapies and immunotherapies will be key to developing combination approaches 
for the treatment of SCLC. These strategies have the potential to overcome and 
reverse resistance to treatments, so as to provide further clinical benefit for patients 
with SCLC.  
 
Taking all this together, we therefore propose a novel paradigm for SCLC that will 
incorporate the upfront and sequential molecular analyses of patient tissue and 
functional imaging studies to optimally select and monitor patients who may benefit 
from such treatments (Figure 3). With this treatment pathway, patients with SCLC 
should undergo a tumour biopsy at diagnosis to obtain suitable tissue for molecular 
analysis alongside the collection of blood specimens for the isolation of CTCs, cpDNA 
and microRNA (miRNA) (Figure 3). Such translational studies may identify genetic 
aberrations and molecular signatures that predict treatment response and resistance 
to therapies. In addition, co-clinical studies with patient tumour and/or CTC derived 
xenografts (PDX) may potentially be used to guide therapeutic strategies for 
individual patients. These models have already shown promise with CTC derived 
xenografts from patients with SCLC [84]. One limitation currently is the time taken to 
grow PDXs as clinically SCLC progresses rapidly and treatment decisions may be 
required prior to knowledge being obtained from such model systems. However, as 
technologies develop, these PDXs may have a critical role in guiding therapeutic 
strategies to overcome drug resistance and therefore play an important role in 
delivering precision medicine in SCLC. Overall, these hypothesis-testing, biomarker-
driven translational studies have the potential to identify patients most likely to 
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respond to targeted therapies, immunotherapies and ADCs, and to provide greater 
and more durable clinical benefit to patients with SCLC. Furthermore, serial 
collection of tissue, CTCs, cpDNA and miRNA, with the development of PDX models, 
will enable ‘real-time’ monitoring with sequential molecular analyses of tumour 
biology while on targeted treatment and at progression. 
 
Conclusions 
SCLC has lagged behind other tumour types in terms of a canvas for novel anti-
cancer drug discovery and biomarker development. In the future, it is likely that with 
our increased understanding of the underlying biology of SCLC and the identification 
and validation of molecular signatures associated with this disease, we may finally 
begin to see a new era of effective targeted agents, immunotherapeutics and ADCs 
developed for the treatment of SCLC. 
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FIGURES  
 
Figure 1: Molecular targets in small cell lung cancer 
  
The figure simplifies the complex network of plasma membrane (PM) receptors, 
intracellular signaling pathways and cellular functions that have been implicated in 
small cell lung cancer (SCLC) development and progression. Targeted therapies 
(blue) that impact these pathways have been investigated in SCLC. Genetic 
aberrations identified in SCLC that are actionable (green) and non-actionable (red) 
are shown. Targets include the epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor receptors (VEGFR), vascular endothelial growth factor 
(VEGF), stem cell factor receptor (C-Kit), insulin-like growth factor receptor (IGFR), 
rat sarcoma (RAS), B-cell lymphoma (BCL-2), mammalian target of rapamycin 
(mTOR), Src and Poly-ADP ribose polymerase (PARP). Therapies highlighted have 
activity against multiple targets (*). 
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Figure 2: Targeting the immune system in small cell lung cancer 
 
Initial T-cell activation occurs within lymph nodes (priming phase). Tumour antigen 
(Ag) is presented by the major histocompatibility complex (MHC) of the antigen 
presenting cells (APC) to the T-cell receptor (TCR) of the T-cell. This is followed by 
antigen independent coregulatory signals in which CD28 on the T-cell binds B7 on 
the APC leading to T-cell activation and mobilisation. Cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4) that is expressed on the activated T-cell competes with 
CD28 for binding to B7 and down regulates the T-cell response. Activated T-cells 
mobilise to the tumour microenvironment and if they recognise antigens expressed 
on the MHC of the tumour cell they proliferate, release cytolytic enzymes and 
secrete cytokines that attract other members of the immune system and eliminate 
the tumour (effector phase). Programmed cell death protein-1 (PD-1) is found on the 
surface of activated T-cells where it binds to its ligands PD-L1, causing T-cell 
inhibition and down regulation of the acquired T-cell response. Tumour cells may 
hijack this pathway by expressing PD-L1 on their cell surface and directly suppressing 
anti-tumour cytotoxic T-cell activity and evading the immune system. 
Immunotherapies (blue) inhibit down regulation of the immune response. 
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Figure 3: Future treatment paradigm for small cell lung cancer 
 
In the future, patients diagnosed with SCLC should routinely undergo tissue biopsy 
and serial whole blood sampling to isolate circulating tumour cells (CTCs), circulating 
plasma DNA (cpDNA) and/or microRNA (miRNA) for translational studies (pale blue 
boxes). These studies will provide molecular analysis of individual patient tumours 
and development of patient derived xenografts to determine therapies (orange 
shading) for patients who undergo observation, maintenance therapy or eventual 
treatment of relapsed disease. Functional imaging will be assessed alongside 
molecular studies to identify patients with progressive disease at an early stage. 
Patients that receive targeted therapy (T) will have ongoing translational studies 
from serial collections (blue shading) to determine molecular changes that predict 
resistance to current therapies (strategy 1, strategy 2 and strategy 3). At progressive 
disease (PD; red shading) molecular analysis will allow adaption/addition of therapy 
(A, B, C, D, E and F) to overcome resistance and provide further clinical benefit for 
patients. Immunotherapy should be considered in patients without actionable 
molecular changes or patients with PDL-1 positive tumours. *PD-L1 testing currently 
is very heterogeneous and extreme caution should be used when applying it as a 
biomarker of response. It is likely that selection biomarkers for PD-L1/PD-1 inhibitors 
will involve additional factors, such as non-synonymous mutational load. Patients 
expressing antigens for antibody-drug conjugate (ADCs) should be considered for 
such therapies. 
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TABLES 
Table 1: Targeted therapies in first line treatment of small cell lung cancer 
Putative 
Target 
Agent Author Phase Therapy Setting Outcome 
Targeting angiogenesis 
VEGF-A Bevacizumab Pujol2015 
Patton2006 
Spigel2008 
Ready2011 
Spigel2009 
Spigel2011 
II/III 
II 
II 
II 
II 
II 
Combination 
Monotherapy 
Combination 
Combination 
Combination 
Combination 
F (M) R 
M 
F (M) 
F  
F (M) 
F (M) R 
Negative 
15m OS 
Stopped 
7m PFS, 11.6m OS 
9.1m TTP, 12.1m 
Negative 
RAF-1, 
VEGFR-2, 
VEGFR-3 
and PDGFRβ 
Sorafenib Sharma2014 II 
 
Combination 
 
F (M) 
 
7.4m OS 
 
VEGFR-1, 
VEGFR-2, 
VEGFR-3, 
PDGFR, c-
KIT, FLT-3 
and RET 
Sunitinib Spigel2012 
Ready2015 
 
II 
II 
 
Monotherapy 
Monotherapy 
 
M 
M R 
 
7.6m PFS 
Improved PFS not OS 
VEGFR-2, 
EGFR and 
RET 
Vandetanib Arnold2007 II Monotherapy M R Negative 
Targeting cell signaling 
BCR-Abl, c-
KIT and 
PDGFR 
Imatinib Johnson2003 
Spigel2007 
Schneider2010 
II 
II 
II 
Monotherapy 
Monotherapy 
Monotherapy 
F 
M 
F (M) 
0.8m TTP 
5.4m PFS, 8.4m OS 
4.3m PFS, 7.8m OS 
mTOR Temsirolimus  Pandya2007 II Monotherapy M  2.5m PFS 
IGF1R Cixutumumab Belani2013 II Combination F R Negative 
Smoothened Vismodegib Belani2013 II Combination F R Negative 
Targeting apoptosis 
BCL-2 Oblimersen Rudin2008 II Combination F Negative 
BCL-2, MCL-
1, BCL-W, 
BCL-XL 
Obatoclax Langer2014 II Combination F Negative 
Targeting DNA repair defects 
PARP Veliparib 
Olaparib 
Owonikoko2014 
Ongoing 
I 
II 
Combination 
Monotherapy 
F 
M R 
Negative 
ISRCTN73164486 
Targeting the immune system  
CTLA-4 Ipilimumab Reck2013 
Ongoing 
Ongoing 
Ongoing 
II 
II 
II 
III 
Combination 
Combination 
Combination 
Combination 
F 
F 
F (M) 
F 
Improved iRPFS 
NCT01331525 
NCT02046733 
NCT01450761 
 
VEGF – Vascular endothelial growth factor; VEGFR – Vascular endothelial growth factor receptor; 
PDGFR – Platelet derived growth factor receptor; c-KIT – Stem cell factor receptor; FLT3 – FMS-like 
tyrosine kinase 3; RET – Rearranged during transfection tyrosine kinase; mTOR - mammalian target of 
rapamycin; IGFR – Insulin like growth factor receptor; BCL-2 – B-cell lymphoma; MCL-1 – Myeloid cell 
leukemia 1; HDAC – Histone deacetylase; F – First-line; F (M) – First-line followed by maintenance; S – 
Second-line; S (M) – Second-line followed by maintenance; R – Randomised; PFS – Progression free 
survival; TTP – Time to progression; OS – Overall survival; m – Months; CS – Case study 
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Table 2: Targeted therapies in treatment of relapsed small cell lung cancer 
Putative Target Agent Ref Phase Therapy Setting Outcome 
Targeting angiogenesis 
VEGF-A Bevacizumab Jalal2010 
Waterhouse2010 
Mountzios2012 
II 
II 
II 
Combination 
Combination 
Combination 
R (M) 
R 
R 
14.7w PFS, 30w OS 
17.4w PFS, 31.6w 
OS 
2.7m PFS, 6.3m OS 
RAF-1, VEGFR-2, VEGFR-3 
and PDGFRβ 
Sorafenib Gitlitz2010 II 
 
Monotherapy R 6.7m OSPS, 5.3m 
OSPR 
VEGFR-1, VEGFR-2, VEGFR-3, 
PDGFR, c-KIT, FLT-3 and RET 
Sunitinib Han2013 II Monotherapy R 1.4m PFS, 5.6m OS 
VEGFR-1 and VEGFR-2 Aflibercept Allen2014 II Combination R Ra Negative 
VEGFR-1, VEGFR-2 and 
VEGFR-3, PDGF and c-Kit 
Pazopanib Gandhi2012 
 
II 
 
Monotherapy 
 
R 
 
14.1w PFS 
 
Targeting cell signaling 
EGFR Gefitinib Moore2006 II Monotherapy R 50d TTP 
BCR-Abl, c-KIT and PDGFR Imatinib Johnson2003 
Krug2005 
II 
II 
Monotherapy 
Monotherapy 
R 
R 
1.2m TTP 
All PD by 4w (n=12) 
mTOR Everolimus Tarhini2010 II Monotherapy R 1.3m PFS, 6.7m OS 
Targeting apoptosis 
BCL-2, BCL-W, BCL-XL Navitoclax Rudin2012 II Monotherapy R 1.5m PFS, 3.2m OS 
BCL-2, BCL-XL, BCL-W, MCL-1 Gossypol Heist2010 I/II Combination R 17.4w PFSPS, 11.7w 
PR 
Proteasome Bortezomib Lara2006 II Monotherapy R 1m PFS, 3m OS 
HDAC Panobinostat De Marinis2013 II Monotherapy R Negative 
Targeting DNA repair defects 
PARP BMN673 Wainberg2014 I Monotherapy R 18% RR 
Targeting the immune system 
PD-1/CTLA-4 Nivolumab 
Ipilimumab 
Antonia2015 I/II Combination R Nivolumab 18% 
ORR and 4.4m OS, 
Combination 17% 
ORR and 8.2m OS 
Antibody-drug conjugates 
CD56 Lorvotuzumab 
mertansine 
Beck2012 I Monotherapy R 25% PR/SD 
DLL3 Rovalpituzumab 
tesirine 
Rudin2015 I Monotherapy R  
 
VEGF – Vascular endothelial growth factor; VEGFR – Vascular endothelial growth factor receptor; 
PDGFR – Platelet derived growth factor receptor; c-KIT – Stem cell factor receptor; FLT3 – FMS-like 
tyrosine kinase 3; RET – Rearranged during transfection tyrosine kinase; mTOR - mammalian target of 
rapamycin; BCL-2 – B-cell lymphoma; MCL-1 – Myeloid cell leukemia 1; HDAC – Histone deacetylase; 
CD56 – Neural cell adhesion molecule; DLL3 – delta-like 3;  F – First-line; F (M) – First-line followed by 
maintenance; R – Relapsed; R (M) – Relapsed followed by maintenance; Ra – Randomised; PFS – 
Progression free survival; TTP – Time to progression; OS – Overall survival; m – Months; 
PR
 – Platinum 
resistant; 
PS
 –Platinum sensitive; d – Days; PR – Partial response; SD – Stable disease 
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Table 3: Molecular basis of small cell lung cancer 
 
Ref Bordi et al 
2014 
Ross et al 
2014* 
Wakuda et al 2014 Umemura et 
al 2014* 
Rudin et al 2012* Peifer et al 2012* 
Patients 113 98 60 47 36 99 
Technique DNA from 
FFPE 
DNA from 
FFPE 
DNA from FFPE 
(50), FF (8) and 
pleural effusions (7) 
DNA from 
FFPE (43) and 
MFPE (12). 
DNA from FF DNA from FF 
Coverage 6 gene 
panel 
236 cancer 
genes 
9 gene panel Whole exome 
and copy 
number 
analysis 
Whole exome, 
transcriptome and 
copy number 
analysis 
Whole exome 
sequencing and 
transcriptome 
analysis 
Aberrations Mutation Mut and amp Mut and amp Mut and amp Mut and amp Mut and amp 
EGFR 1.8% 5% 1.7% NR Mutation hotspots 
TP53 
RB1 
PIK3CA 
CDKN2A 
PTEN 
EP300 
MLL2 
 
Mutation 
clustering 
PIK3CA 
AKT1-3 
MTOR 
NOTCH1-3 
SMO 
SOX 3-6,9,11,14,17 
 
Amplification 
SOX2 
MYC 
KIT 
 
 
 
 
Mutations 
TP53 
RB1 
CREBBP 
EP300 
MLL 
PTEN 
SLIT2 
EPHA7 
 
Amplification 
MYC family 
FGFR1  
 
BRAF 0% NR 0% 2.1% 
c-KIT 0% 7%  NR 
c-MET 4.4% NR 1.7% NR 
KRAS 0% 5% 1.7% 2.1% 
NRAS  NR 0% NR 
PDGFR 0% NR  NR 
TP53  86%  78.7% 
RB1  54%  44.7% 
MLL2  17%  NR 
RICTOR  10%  8.5% 
MYCL1  8%  8.5% 
FGF10  8%  NR 
LRP1B  7%  NR 
PIK3CA  6% 15% 6.4% 
PTEN  5%  4.3% 
MYST3  5%  NR 
MEK1  NR 0% 4.3% 
AKT  NR 1.7% 12.8% 
HER2  NR 0% NR 
CREBBP  3%  4.3% 
 
DNA – deoxyribose nucleic acid; FFPE – formalin fixed paraffin embedded; FF – fresh frozen; Mut – 
mutation; Amp – amplification; NR – not recorded; Not assessed (grey shading); *please see original 
references for exhaustive list of aberrations. 
 
 
 
 
 
 
 
 
